Verrica Pharmaceuticals Inc. (VRCA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
44 West Gay Street
West Chester, PA 19380
United States of America (the)
Phone
484 453 3300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
71
First IPO Date
June 15, 2018
| Name | Title | Pay | Year Born |
| Jayson Rieger | President, Chief Executive Officer & Director | 391,167 | 1976 |
| Noah L. Rosenberg | Chief Medical Officer | 243,316 | 1967 |
| John J. Kirby | Interim Chief Financial Officer | 532,500 | 1972 |
| Chris Chapman | Chief Commercial Officer | 635,379 | N/A |
| Eugene Scavola | Executive Vice President of Technical Operations | 0 | N/A |
| Bradley J. Catalone | Head of Drug Development | 0 | N/A |
| David Zawitz | COO, Chief Legal Officer & Secretary | 0 | 1981 |
Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.